BRAF V600E mutation was confirmed in tumor specimens from all patients using the MEBGENTM BRAF 3 kit (Medical & Biological Laboratories Co., Ltd., Japan), which employs polymerase chain reaction with sequence-specific oligonucleotide probes (PCR-rSSO). This evidence concerns the gene BRAF and neoplasm.